Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Rutgers research reveals mechanism to prevent benign kidney tumor from becoming cancerous

Research from investigators at Rutgers Cancer Institute of New Jersey examining the inner workings of a rare non-cancerous (benign) kidney tumor has revealed a mechanism to prevent this type of tumor from becoming cancerous (malignant).

22 Nov 2015

Meat-rich diet may increase kidney cancer risk

A new study indicates that a meat-rich diet may increase the risk of developing kidney cancer through mechanisms related to particular cooking compounds. Also, these associations may be modified by genetic susceptibility to kidney cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study illustrates how diet and genetics may interact to impact cancer risk.

10 Nov 2015

Brain metastases evolve ‘clinically actionable’ mutations

Brain metastatic disease shows branched evolution from the primary tumour, suggest preliminary findings from the largest massively parallel sequencing study of paired samples performed so far.

7 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

21 Sep 2015

Tolerability benefits with sunitinib schedule switch

Switching sunitinib treatment from a 4/2 to a modified 2/1 schedule can improve the tolerability profile for patients with metastatic renal cell carcinoma, say researchers.

17 Sep 2015

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study.

17 Sep 2015

Active surveillance ‘viable option’ for SRM management

US researchers find no significant difference in survival outcomes between patients with small renal masses who opt for active surveillance and those who choose immediate treatment.

17 Sep 2015

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.

11 Sep 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma.

27 Jun 2015

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced an independent data monitoring committee (IDMC) has recommended the continuation of the company’s pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) following the first of three planned interim data analyses.

5 Jun 2015

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.

2 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Hutchison China MediTech Limited, today announces that AstraZeneca AB, Hutchison MediPharma Limited's collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer.

1 Jun 2015

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Rutgers research reveals mechanism to prevent benign kidney tumor from becoming cancerous

Meat-rich diet may increase kidney cancer risk

Brain metastases evolve ‘clinically actionable’ mutations

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

New drug works better than current treatments for advanced kidney cancer

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Patients with advanced kidney cancer benefit from cabozantinib treatment

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Tolerability benefits with sunitinib schedule switch

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

Active surveillance ‘viable option’ for SRM management

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Your complete guide to renal proximal tubule cells eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Your complete guide to renal proximal tubule cells eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in